-
-
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers
-
-
Radiation therapy techniques and treatment-related toxicity in the PORTEC-3 trial
-
-
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement
-
-
Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial
-
-
Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial
-
-
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
-
-
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
-
-
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
-
-
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3)
-
-
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
-
-
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
-
-
Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects
-
-
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
-
-
The selective orexin-2 antagonist JNJ-42847922(MIN-202) improves sleep in patients with primary insomnia
-
-
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
-
-
PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN AN ANZGOG SUBSTUDY OF THE PORTEC-3 INTERGROUP RANDOMIZED CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY IN HIGH RISK ENDOMETRIAL CANCER